The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
400
Proportion of subjects with a mean reduction of greater than or equal to 30% in iPTH at 32 weeks
Changes in iPTH at 32 weeks.
Safety and tolerability of cinacalcet at 32 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.